Static Chart Celltrion, Inc.

Equities

End-of-day quote Korea S.E. Other stock markets 11/09/2024			5-day change	1st Jan Change
190,700.00 ^KRW	-2.60%		-3.20%	-5.36%

08-29	Celltrion Usa Partners with Express Scripts and Cigna Healthcare to Expand Access to Zymfentra® (Infliximab-Dyyb), the First and Only Fda-Approved Subcutaneous Infliximab on Their Medical Benefit Formulary	CI
08-26	European Commission Approves Celltrion's SteQeyma (CT-P43) A Biosimilar to Stelara (ustekinumab), for the Treatment of Multiple Chronic Inflammatory Diseases	CI

Duration

Period